Sunshine Heart's public offering pulls in $18M

Sunshine Heart ($SSH) has successfully closed a public offering of more than 2.8 million shares of common stock, reeling $18 million in the process. The company, which is based in Minnesota and Australia, priced the shares at $7 each. Funds will likely support continued development of Sunshine's C-Pulse heart assist implant, which is designed to treat moderate to severe heart failure. Earlier this month, Sunshine won conditional FDA approval for the device, allowing it to be used at all U.S. sites taking part in the company's North American feasibility trial. Investors went wild, driving the share price up 18%. Plans call for submitting an investigational device exemption later this year, after which Sunshine will launch a pivotal U.S. trial. Release

Suggested Articles

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.

Cybernet Manufacturing, maker of medical-grade computer monitors, has unveiled a new, large touchscreen designed to protect against infections.

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in complications.